Sanitam Partners LLC - 08 Apr 2025 Form 4/A - Amendment Insider Report for Matinas BioPharma Holdings, Inc. (MTNB)

Reporting relationship: 10%+ Owner
Issuer ticker: MTNB
Reported as of: 08 Apr 2025
Net transaction value: +$703,000
SEC form: 4/A - Amendment
Accepted by SEC: 10 Apr 2025, 16:45:03 UTC
Original report date: 28 Feb 2025
Prior SEC filing: 28 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Adam Stern

Key filing fact

Sanitam Partners LLC filed Form 4/A - Amendment for Matinas BioPharma Holdings, Inc. (MTNB) on 10 Apr 2025.

Key facts

This page summarizes Sanitam Partners LLC's Form 4/A - Amendment filing for Matinas BioPharma Holdings, Inc. (MTNB).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 10 Apr 2025, 16:45.

Change

Previous filing in this sequence was filed on 28 Feb 2025.
Current net transaction value: +$703,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MTNB transaction Derivative

Series C Convertible Preferred Stock

Purchase

Transaction value: $703,000
Shares: +703
Change %: +100%
Price: $1000.00^*
Shares after: 1,406
Date: 08 Apr 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,199,659
Exercise price: $0.5860
Footnotes: F1, F2, F3

MTNB transaction Derivative

Warrants

Purchase

Transaction value
Shares: +2,399,318
Change %: +100%
Price
Shares after: 4,798,636
Date: 08 Apr 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,399,318
Exercise price: $0.6446
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Pursuant to the Securities Purchase Agreement, dated February 13, 2025, Sanitam purchased an aggregate of 1,406 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.0001 per share (the "Preferred Stock") with a stated value of $1,000 per share of Preferred Stock, and 4,798,636 Warrants for gross proceeds of $1,406,000.00. The Preferred Stock and Warrants were sold in two tranches with each tranche consisting of 703 shares of Preferred Stock and 2,399,318 Warrants.

Footnote F2

Each holder of Preferred Stock is entitled to vote on an as-converted to Common Stock basis with a per share voting price of $0.6393, granting Sanitam voting power from the Preferred Strock of up to 30.2% of the outstanding Common Stock. Sanitam's beneficial ownership is subject to a 9.99% limit on the shares of Common Stock issuable upon conversion of the Preferred Stock and a 4.99% limit on the shares of Common Stock issuable upon exercise of the Warrants.

Footnote F3

N/A